LHXL3HARRIS TECHNOLOGIES, INC....

NYSE l3harris.com


$ 235.20 $ 3.44 (1.48 %)    

Monday, 15-Jul-2024 15:20:31 EDT
QQQ $ 497.23 $ 0.49 (0.1 %)
DIA $ 403.25 $ 0.65 (0.16 %)
SPY $ 562.47 $ 0.29 (0.05 %)
TLT $ 92.79 $ -0.17 (-0.18 %)
GLD $ 223.99 $ 0.57 (0.26 %)
$ 231.04
$ 231.76
$ 0.00 x 0
$ 240.00 x 192
$ 231.76 - $ 235.25
$ 157.61 - $ 233.85
793,407
na
43.82B
$ 0.88
$ 37.36
TBD
na
na ($ 0.02)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 04-26-2024 03-29-2024 10-Q
2 02-20-2024 12-29-2023 10-K
3 10-27-2023 09-29-2023 10-Q
4 07-26-2023 06-30-2023 10-Q
5 04-28-2023 03-31-2023 10-Q
6 02-24-2023 12-30-2022 10-K
7 10-31-2022 09-30-2022 10-Q
8 07-29-2022 07-01-2022 10-Q
9 04-29-2022 04-01-2022 10-Q
10 02-25-2022 12-31-2021 10-K
11 10-29-2021 10-01-2021 10-Q
12 08-04-2021 07-02-2021 10-Q
13 05-03-2021 04-02-2021 10-Q
14 03-01-2021 01-01-2021 10-K
15 11-02-2020 10-02-2020 10-Q
16 08-04-2020 07-03-2020 10-Q
17 05-07-2020 04-03-2020 10-Q
18 03-03-2020 01-03-2020 10-K
19 10-31-2019 09-27-2019 10-Q
20 08-22-2019 06-28-2019 10-K
21 05-02-2019 03-29-2019 10-Q
22 01-30-2019 12-28-2018 10-Q
23 10-26-2018 09-28-2018 10-Q
24 08-27-2018 06-29-2018 10-K
25 05-03-2018 03-30-2018 10-Q
26 01-31-2018 12-29-2017 10-Q
27 10-31-2017 09-29-2017 10-Q
28 08-29-2017 06-30-2017 10-K
29 05-03-2017 03-31-2017 10-Q
30 02-03-2017 12-30-2016 10-Q
31 11-02-2016 09-30-2016 10-Q
32 08-29-2016 07-01-2016 10-K
33 05-04-2016 04-01-2016 10-Q
34 02-03-2016 01-01-2016 10-Q
35 11-06-2015 10-02-2015 10-Q
36 08-31-2015 07-03-2015 10-K
37 05-06-2015 04-03-2015 10-Q
38 02-10-2015 01-02-2015 10-Q
39 10-29-2014 09-26-2014 10-Q
40 08-25-2014 06-27-2014 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 pfizer-l3harris-technologies-and-more-cnbcs-final-trades

Pfizer selected Danuglipron, its once-daily weight loss drug, for continued advancement based on an ongoing pharmacokinetic study.

Core News & Articles

- Reuters

 josh-brown-sees-a-breakout-brewing-in-3m-stock-why-hes-the-most-excited-hes-been-in-25-years

Ritholtz Wealth Management's Josh Brown is putting money to work outside of tech as he anticipates money rolling into other...

 us-air-force-awards-contract-to-l3harris-technologies-for-b-52-modernization

- Reuters

Core News & Articles

Sidus Space, Inc. (NASDAQ:SIDU) (the "Company" or "Sidus"), a multi-faceted Space and Data-as-a-Service satelli...

 wells-fargo-maintains-overweight-on-l3harris-technologies-raises-price-target-to-245

Wells Fargo analyst Matthew Akers maintains L3Harris Technologies (NYSE:LHX) with a Overweight and raises the price target f...

 jp-morgan-maintains-overweight-on-l3harris-technologies-raises-price-target-to-250

JP Morgan analyst Seth Seifman maintains L3Harris Technologies (NYSE:LHX) with a Overweight and raises the price target from...

 barclays-maintains-overweight-on-l3harris-technologies-raises-price-target-to-245

Barclays analyst David Strauss maintains L3Harris Technologies (NYSE:LHX) with a Overweight and raises the price target from...

 rbc-capital-maintains-outperform-on-l3harris-technologies-raises-price-target-to-250

RBC Capital analyst Ken Herbert maintains L3Harris Technologies (NYSE:LHX) with a Outperform and raises the price target fro...

 l3harris-ceo-chris-kubasik-on-5-workforce-cut-says-was-right-thing-to-do-for-the-business

- CNBC Interview